How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013
Mark Danese, Michelle Gleeson, Marc Halperin1 et al.
Key Points:
R+Chemo vs chemotherapy alone in US studied for DLBCL, FL and CLL
Population effectiveness model comprised of 3 modules: epidemiology, utilization and survival from 1998-2013
For all three cancers, 289,793 cumulative life years saved (95% UI, 248,300-330,618) from 1998 to 2013.
For CLL, 14,398 patients treated with R+Chemo, and additional 10,132 (95% UI 4,469-15,998) life years were lived.
Implications:
- For DLBCL, FL and CLL patients as first-line therapy, within 180 days of diagnosis in US, around 290,000 cumulative life years saved by adding rituximab to the chemotherapy.
View the original abstract on the ASH website.
